Related Experiment Video
Updated: Jun 7, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Chemoradiotherapy for cervical cancer in 2010
Ann H Klopp1, Patricia J Eifel
1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Unit 1202, 1515 Holcombe Boulevard, Houston, TX 77030, USA. aklopp@mdanderson.org
Current Oncology Reports
|November 3, 2010
Summary
Concurrent chemoradiation significantly improved cervical cancer outcomes. Future research focuses on novel agents with reduced toxicity to further advance treatment efficacy and patient tolerability.
Area of Science:
- Gynecologic Oncology
- Radiation Oncology
- Medical Oncology
Background:
- Concurrent chemotherapy and radiotherapy is a cornerstone in definitive cervical cancer treatment.
- Platinum-based chemotherapy combined with radiation has demonstrated significant improvements in local control and survival rates.
- Despite successes, treatment toxicities limit further advancements.
Purpose of the Study:
- To review the impact of concurrent chemoradiation in cervical cancer.
- To discuss the limitations and future directions in developing novel therapeutic agents.
- To explore strategies for improving supportive care and minimizing treatment-related toxicities.
Main Methods:
- Review of seminal trials and ongoing research in cervical cancer treatment.
- Analysis of efficacy and toxicity profiles of current and investigational agents.
- Discussion of challenges in managing treatment side effects.
Main Results:
- Concurrent chemoradiation offers substantial benefits in local control, progression-free survival, and overall survival for cervical cancer.
- Existing platinum-based chemoradiation regimens approach the limits of patient tolerability.
- Limited success in identifying new agents due to overlapping toxic effects.
Conclusions:
- Future progress in cervical cancer treatment hinges on novel agents with non-overlapping toxicities.
- Improving supportive care is crucial for enhancing patient management.
- Minimizing radiation-induced toxicities remains a key objective for optimizing treatment outcomes.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...